GlaxoSmithKline Pakistan Ltd (GLAX)

Currency in PKR
382.00
-5.15(-1.33%)
Closed·
High dividend Yield
GLAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
376.11384.99
52 wk Range
293.09469.90
Key Statistics
Bid/Ask
381.11 / 382.32
Prev. Close
387.15
Open
384.99
Day's Range
376.11-384.99
52 wk Range
293.09-469.9
Volume
438.97K
Average Volume (3m)
331.67K
1-Year Change
-17.1198%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GLAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
561.67
Upside
+47.03%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low earnings multiple
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc.

Employees
1606
Market
Pakistan

Compare GLAX to Peers and Sector

Metrics to compare
GLAX
Peers
Sector
Relationship
P/E Ratio
12.3x18.5x−0.5x
PEG Ratio
0.230.500.00
Price/Book
3.7x3.4x2.6x
Price / LTM Sales
1.9x1.8x3.2x
Upside (Analyst Target)
42.1%9.4%45.2%
Fair Value Upside
Unlock22.0%6.4%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 561.67
(+47.03% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 31.48%
Dividend Yield
4.30%
Industry Median 3.89%
Annualized payout
17.00
Paid annually
5-Years Growth
+21.20%
Growth Streak

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
11.59 / --
Revenue / Forecast
21.41B / --
EPS Revisions
Last 90 days

GLAX Income Statement

People Also Watch

150.01
SYSE
-1.61%
280.50
ENGO
-1.15%
80.80
INTR
-0.32%
89.99
FYBL
-1.37%

FAQ

What Is the GlaxoSmithKline Pakistan (GLAX) Stock Price Today?

The GlaxoSmithKline Pakistan stock price today is 382.00 PKR.

What Stock Exchange Does GlaxoSmithKline Pakistan Trade On?

GlaxoSmithKline Pakistan is listed and trades on the Karachi Stock Exchange.

What Is the Stock Symbol for GlaxoSmithKline Pakistan?

The stock symbol for GlaxoSmithKline Pakistan is "GLAX."

Does GlaxoSmithKline Pakistan Pay Dividends? What’s The Current Dividend Yield?

The GlaxoSmithKline Pakistan dividend yield is 4.39%.

What Is the GlaxoSmithKline Pakistan Market Cap?

As of today, GlaxoSmithKline Pakistan market cap is 121.65B PKR.

What Is GlaxoSmithKline Pakistan's Earnings Per Share (TTM)?

The GlaxoSmithKline Pakistan EPS (TTM) is 31.48.

When Is the Next GlaxoSmithKline Pakistan Earnings Date?

GlaxoSmithKline Pakistan will release its next earnings report on Jun 03, 2026.

From a Technical Analysis Perspective, Is GLAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has GlaxoSmithKline Pakistan Stock Split?

GlaxoSmithKline Pakistan has split 9 times.

How Many Employees Does GlaxoSmithKline Pakistan Have?

GlaxoSmithKline Pakistan has 1606 employees.

What is the current trading status of GlaxoSmithKline Pakistan (GLAX)?

As of Apr 23, 2026, GlaxoSmithKline Pakistan (GLAX) is trading at a price of 382.00 PKR, with a previous close of 387.15 PKR. The stock has fluctuated within a day range of 376.11 PKR to 384.99 PKR, while its 52-week range spans from 293.09 PKR to 469.90 PKR.

What Is GlaxoSmithKline Pakistan (GLAX) Price Target According to Analysts?

The average 12-month price target for GlaxoSmithKline Pakistan is 561.67 PKR, with a high estimate of 610 PKR and a low estimate of 525 PKR. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +47.03% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.